These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15578879)

  • 1. Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.
    Adcock DM; Koftan C; Crisan D; Kiechle FL
    Arch Pathol Lab Med; 2004 Dec; 128(12):1360-3. PubMed ID: 15578879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
    Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
    Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.
    Gong IY; Tirona RG; Schwarz UI; Crown N; Dresser GK; Larue S; Langlois N; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Carrier M; Forgie M; Wells PS; Kim RB
    Blood; 2011 Sep; 118(11):3163-71. PubMed ID: 21725053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
    Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
    Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment.
    Skov J; Bladbjerg EM; Leppin A; Jespersen J
    Thromb Res; 2013 Feb; 131(2):125-9. PubMed ID: 23159229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
    Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
    Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Warfarin in the treatment of antiphospholipid syndrome].
    Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
    Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.
    Linder MW; Looney S; Adams JE; Johnson N; Antonino-Green D; Lacefield N; Bukaveckas BL; Valdes R
    J Thromb Thrombolysis; 2002 Dec; 14(3):227-32. PubMed ID: 12913403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
    Voora D; Eby C; Linder MW; Milligan PE; Bukaveckas BL; McLeod HL; Maloney W; Clohisy J; Burnett RS; Grosso L; Gatchel SK; Gage BF
    Thromb Haemost; 2005 Apr; 93(4):700-5. PubMed ID: 15841315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.
    Sanderson S; Emery J; Higgins J
    Genet Med; 2005 Feb; 7(2):97-104. PubMed ID: 15714076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.